Fatty acid-binding protein 1 (FABP1), also known as liver-type FABP (L-FABP), is a small cytoplasmic protein predominantly expressed in hepatocytes and intestinal epithelial cells. It plays a critical role in intracellular fatty acid transport, metabolism, and signaling by binding hydrophobic ligands such as long-chain fatty acids, bile acids, and eicosanoids. FABP1 antibodies are essential tools for studying its expression, localization, and function in lipid homeostasis, inflammation, and metabolic disorders.
These antibodies are widely used in research applications, including Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), to investigate FABP1's tissue distribution and regulation under physiological or pathological conditions. Elevated FABP1 levels in serum or urine are recognized as biomarkers for liver injury, intestinal ischemia, and certain cancers, making FABP1 antibodies valuable in diagnostic assays.
Studies using FABP1-specific antibodies have linked its dysregulation to non-alcoholic fatty liver disease (NAFLD), atherosclerosis, and diabetes. Additionally, FABP1 knockout models, validated by antibody-based detection, highlight its role in mitigating oxidative stress and inflammation. Commercial FABP1 antibodies are typically raised against conserved epitopes, ensuring cross-reactivity in human, mouse, and rat samples. Validation steps, such as knockout controls or peptide blocking, are critical to confirm specificity, given the homology among FABP family members.